In vitro pharmacological characterization of the potent, lung selective pan-JAK inhibitor TD-8236
R. Sana (South San Francisco, United States of America), W. Krey-Epstein (South San Francisco, United States of America), E. Sandvik (South San Francisco, United States of America), E. Gordon (South San Francisco, United States of America), S. Calhoun (South San Francisco, United States of America), E. Kaufman (South San Francisco, United States of America), J. Budman (South San Francisco, United States of America), P. Fatheree (South San Francisco, United States of America), M. Kleinschek (South San Francisco, United States of America)
Source: International Congress 2019 – Advances in asthma pharmacology
Session: Advances in asthma pharmacology
Session type: Poster Discussion
Number: 3872
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
R. Sana (South San Francisco, United States of America), W. Krey-Epstein (South San Francisco, United States of America), E. Sandvik (South San Francisco, United States of America), E. Gordon (South San Francisco, United States of America), S. Calhoun (South San Francisco, United States of America), E. Kaufman (South San Francisco, United States of America), J. Budman (South San Francisco, United States of America), P. Fatheree (South San Francisco, United States of America), M. Kleinschek (South San Francisco, United States of America). In vitro pharmacological characterization of the potent, lung selective pan-JAK inhibitor TD-8236. 3872
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
In vitro and in vivo anti-inflammatory activity of the novel PDE4 inhibitor roflumilastSource: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001
Pharmacological properties of a novel PI3Kd inhibitor, DS-1515 Source: International Congress 2018 – Basic pharmacology Year: 2018
Effects of CHF6297, a potent and selective p38a MAPK inhibitor, in murine models of steroid resistant lung inflammation Source: International Congress 2017 – Towards new anti-inflammatory and anti-fibrotic agents Year: 2017
The bronchodilatory and anti-inflammatory effect of MT-810, a novel selective phosphodiesterase-4 (PDE4) inhibitor Source: Eur Respir J 2006; 28: Suppl. 50, 434s Year: 2006
In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profile Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014
In vitro and in vivo characterisation of the novel neutrophil elastase inhibitor BI 1323495 Source: Virtual Congress 2020 – Scientific advances in airway pharmacology Year: 2020
The selective phosphodiesterase 4 inhibitor, cilomilast, inhibits interleukin-8-induced pulmonary neutrophil accumulation in the rabbit Source: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001
In vitro and in vivo pharmacological profile of RP6503, a novel dual PI3K Δ/gamma inhibitor, in pulmonary disease systemsSource: Annual Congress 2013 –Emerging new targets for the treatment of respiratory diseases Year: 2013
The novel phosphodiesterase 4 inhibitor CI-1044 inhibits in vitro LPS-induced TNFα production in whole blood of COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 34s Year: 2001
ONX0912, a novel proteasome inhibitor for the treatment of lung fibrosis? Source: Annual Congress 2012 - New drug targets and pre-clinical models for respiratory diseases Year: 2012
The phosphodiesterase 4 inhibitor SB 207499 selectively inhibits neutrophil functions Source: Eur Respir J 2001; 18: Suppl. 33, 34s Year: 2001
The JAK3 inhibitor CP-690550 is a potent anti-fibrosis agent in a murine model of pulmonary fibrosis induced by bleomycin Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012
Roflumilast N-oxide, a selective PDE4 inhibitor, curbs platelet-leukocyte interactions Source: Annual Congress 2011 - Translational models of disease Year: 2011
Roflumilast N-oxide, a PDE4 inhibitor, curbs bleomycin-induced lung fibroblast activation in vitro Source: Annual Congress 2011 - Airway smooth muscle cells and fibroblasts: cell biology Year: 2011
Identification of mechanism-specific biomarkers to guide development of the lung-selective inhaled pan-JAK inhibitor TD-8236 Source: Virtual Congress 2020 – Asthma science: novel targets and mechanisms Year: 2020
Dose-dependent inhibitory effect of Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, on allergen-induced early and late asthmatic reaction Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002
In-vitro evaluation of a new potent, selective pan-Janus kinase (JAK) inhibitor VR588 Source: International Congress 2015 – New targets and modalities for the treatment of asthma and COPD Year: 2015
In vitro pharmacological profile of SMP-028, a novel potent anti-inflammatory agentSource: Annual Congress 2010 - Models of airways disease Year: 2010
Synergistic anti-tumor effects of vandetanib, an inhibitor of VEGFR and EGFR tyrosine kinase inhibitor, combined with cytotoxic agents in lung cancer cell lines Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010
The novel selective PDE4 inhibitor roflumilast: early onset of efficacy in asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003